Tempest Therapeutics, Inc. (TPST) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87978U2078
Tempest Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -26.58 m USD |
| EBIT | -26.06 m USD |
| Net income | -26.26 m USD |
| Diluted EPS – continuing operations | -6.33 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
More stocks
- LataMed AI Corp. (LMED)
- GAXOS.AI INC. (GXAI)
- Zeo ScientifiX, Inc. (ZEOX)
- Rocky Mountain Chocolate Factory, Inc. (RMCF)
- Adaptimmune Therapeutics PLC (ADAPY)
- Stimcell Energetics Inc. (STME)
- Sky Quarry Inc. (SKYQ)
- Oncotelic Therapeutics, Inc. (OTLC)
- Blue Star Foods Corp. (BSFC)
- Mag Mile Capital, Inc. (MMCP)
- Biofrontera Inc. (BFRI)
- Sonendo, Inc. (SONX)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.